|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.545 AUD | -0.91% |
|
-9.17% | -28.29% |
Medical Developments International Ltd. announced that the US Food and Drug Administration has unconditionally lifted the agency's clinical hold on Penthrox. This means that MVP can immediately begin preparing for its Phase III US clinical trial. As anticipated, the trial will be conducted on a targeted trauma and associated pain patient group.
The company expects that the 2-year trial will commence recruitment in late 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| -28.29% | 30.47M | |
| +28.35% | 676B | |
| +23.58% | 554B | |
| -7.75% | 349B | |
| +14.57% | 318B | |
| +7.22% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -12.07% | 144B |
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED 
